首页 > 市场调查报告书 > 製药

癌症呼吸器

2030 年北美肺癌治疗市场预测 - 区域分析 - 按治疗类型、适应症和最终用户

市场调查报告书

商品编码

1494400

2030 年北美肺癌治疗市场预测 - 区域分析 - 按治疗类型、适应症和最终用户

North America Lung Cancer Therapy Market Forecast to 2030 - Regional Analysis - By Therapy Type, Indication, and End User

出版日期: 2024年03月14日 | 出版商:

The Insight Partners | 英文 79 Pages | 订单完成后即时交付

价格

简介目录图表

2022年北美肺癌治疗市值为151.0592亿美元，预计2030年将达385.5655亿美元；预计2022年至2030年复合年增长率为12.4%。

肺癌病例的增加推动北美肺癌治疗市场

肺癌是全世界死亡的主要原因之一。如果及早诊断，这种类型的癌症可以得到更有效的治疗。因此，肺癌高风险族群需要接受常规检查，以检测肺部癌变的形成。在全球范围内，肺癌是男性最常见的癌症，也是女性第二常见的癌症。根据世界卫生组织 (WHO) 的数据，肺癌是全球男性和女性癌症相关死亡的主要原因。根据世界癌症研究基金会的数据，2020 年全球新增肺癌病例约 220 万例。名。根据加拿大癌症协会估计，预计将有 31,000 名加拿大人被诊断出患有肺癌和支气管癌。这将占 2023 年所有新癌症病例的 13%。在 2023 年所有癌症相关死亡中，这一比例占 24%。因此，全球肺癌发生率的上升促进了肺癌治疗的研发活动，进而推动了市场的成长。

北美肺癌治疗市场概况

美国北美肺癌治疗市场的成长主要是由肺癌病例发生率上升、产品发布和政府措施推动的。肺癌是美国第二常见癌症。根据美国癌症协会的数据，截至 2023 年，美国约有 238,340 名成年人（117,550 名男性和 120,790 名女性）被诊断出患有肺癌；此外，约有 127,070 人（男性 67,160 人，女性 59,910 人）死于此疾病。肺癌占所有癌症死亡的五分之一，使其成为美国癌症死亡的主要原因。根据同一来源，非小细胞肺癌 (NSCLC) 占所有肺癌诊断的 81%。因此，该国肺癌发病率的上升推动了美国肺癌治疗市场的成长。

公司推出的各种治疗肺癌的产品也促进了市场的成长。例如，2021年5月，美国FDA核准Lumakras（sotorasib）作为第一个针对成人非小细胞肺癌患者的标靶治疗药物。这是第一个被批准用于具有 KRAS 突变的肿瘤的标靶治疗，据报告，非小细胞肺癌 (NSCLC) 中约有 25% 的突变。此外，2021年5月，美国FDA加速核准amivantamab-vmjw (Rybrevant)，是一种针对錶皮生长因子(EGF)和MET受体的双特异性抗体，用于治疗含有EGFR外显子20插入的局部晚期或转移性NSCLC成人患者突变。

根据数位策略办公室管理的白宫官方网站 Whitehouse.gov 于 2023 年 5 月发布的报告，社区癌症中心协会 (ACCC) 与阿斯特捷利康建立了合作伙伴关係，以开发和实施透过「农村阿巴拉契亚肺癌筛检计画”，以人为本和可持续的方法来推动美国农村地区的肺癌筛检。阿巴拉契亚地区（包括整个西维吉尼亚州和其他 12 个州的部分地区）的癌症死亡率比美国其他地区高 10%。该措施旨在将肺癌的五年存活率提高一倍。这些措施正在促进美国北美肺癌治疗市场的成长。

北美肺癌治疗市场收入及 2030 年预测（百万美元）

北美肺癌治疗市场细分

北美肺癌治疗市场根据治疗类型、适应症、最终用户和国家进行细分。

根据治疗类型，北美肺癌治疗市场分为非侵入性治疗和微创治疗。到2022年，非侵入性细分市场将占更大份额。

有迹象表明，北美肺癌治疗市场分为非小细胞肺癌和小细胞肺癌。 2022 年，非小细胞肺癌细分市场将占据更大份额。

依最终用户划分，北美肺癌治疗市场分为医院、肿瘤诊所、研究中心等。 2022 年，医院领域占最大份额。

按国家/地区划分，北美肺癌治疗市场分为美国、加拿大和墨西哥。 2022年，美国将主导北美肺癌治疗市场。

Medtronic Plc、RF Medical Co Ltd、Johnson & Johnson、Merck KGaA、Sun Pharmaceutical Industries Ltd、Bioventus Inc、Olympus Corp、Meiji Seika Pharma Co Ltd 和 Advanz Pharma Corp 是北美肺癌治疗领域的一些领先公司市场。

Lung cancer is among the main causes of mortality across the world. This type of cancer can be treated more effectively if it is diagnosed early. Therefore, people at a high risk of lung cancer need to undergo routine testing to detect the formation of cancerous growth inside their lungs. Globally lung cancer is the most common cancer in men and the second most common cancer in women. According to the World Health Organization (WHO), lung cancer is the leading cause of cancer-related deaths globally, in both men and women. As per the World Cancer Research Fund International, ~2.2 million new lung cancer cases were registered worldwide in 2020. According to the American Cancer Society's estimates for lung cancer in the US, ~238,340 new lung cancer cases are likely to be registered in 2023, including 120,790 women and 117,550 men. According to estimates from the Canadian Cancer Society, 31,000 Canadians are expected to be diagnosed with lung and bronchus cancer. This will represent 13% of all new cancer cases in 2023. In addition, lung and bronchus cancer will result in the death of 20,600 Canadian citizens. Of all cancer-related deaths in 2023, this accounts for 24%. Thus, the rising incidence of lung cancer worldwide is contributing to the research and development activities for lung cancer therapy, which is, in turn, driving the market growth.

North America Lung Cancer Therapy Market Overview

The growth of the North America lung cancer therapy market in the US is mainly driven by the increasing incidence of lung cancer cases, product launches, and government initiatives. Lung cancer is the second most common cancer in the US. As per the American Cancer Society, Inc., as of 2023, ~238,340 adults (117,550 men and 120,790 women) in the US have been diagnosed with lung cancer; also, ~127,070 (67,160 in men and 59,910 in women) have succumbed to death due to the disease. Lung cancer accounts for 1 in 5 of all cancer deaths, making it a leading cause of cancer death in the US. As per the same source, NSCLC accounts for 81% of all lung cancer diagnoses. Thus, the increasing incidence of lung cancer in the country fuels the growth of the US lung cancer therapy market.

Various product launches for the treatment of lung cancer by companies are also bolstering the market growth. For instance, in May 2021, the US FDA approved Lumakras (sotorasib) as the first targeted therapy for adult non-small cell lung cancer patients. This is the first targeted therapy that is approved for tumors with KRAS mutation, which reports ~25% of mutations in non-small cell lung cancer (NSCLC). Moreover, in May 2021, the US FDA granted accelerated approval to amivantamab-vmjw (Rybrevant), a bispecific antibody directed against epidermal growth factor (EGF) and MET receptors, for adult patients with locally advanced or metastatic NSCLC that comprises EGFR exon 20 insertion mutations.

As per the report published in the whitehouse.gov, the official website of the White House, managed by the Office of Digital Strategy in May 2023, the Association of Community Cancer Centers (ACCC) and AstraZeneca entered into a partnership for the development and implementation of person-centered and sustainable approaches to drive lung cancer screening in rural America through "Rural Appalachian Lung Cancer Screening Initiative." The cancer mortality rate in the Appalachian region, including all of West Virginia and a few parts of 12 other states, is 10% higher than that of the rest of the US. This initiative aims to double the five-year survival rate for lung cancer. Such initiatives are contributing to the growth of the North America lung cancer therapy market in the US.

North America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Million)

North America Lung Cancer Therapy Market Segmentation

The North America lung cancer therapy market is segmented based on therapy type, indication, end user, and country.

Based on therapy type, the North America lung cancer therapy market is bifurcated into noninvasive and minimally invasive. The noninvasive segment held a larger share in 2022. The minimally invasive segment is further subsegmented into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others.

By indication, the North America lung cancer therapy market is bifurcated into non-small cell lung cancer and small cell lung cancer. The non-small cell lung cancer segment held a larger share in 2022.

By end user, the North America lung cancer therapy market is segmented into hospitals, oncology clinics, research centers, and others. The hospitals segment held the largest share in 2022.

Based on country, the North America lung cancer therapy market is segmented into the US, Canada, and Mexico. The US dominated the North America lung cancer therapy market in 2022.

Medtronic Plc, RF Medical Co Ltd, Johnson & Johnson, Merck KGaA, Sun Pharmaceutical Industries Ltd, Bioventus Inc, Olympus Corp, Meiji Seika Pharma Co Ltd, and Advanz Pharma Corp are some of the leading companies operating in the North America lung cancer therapy market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 North America Lung Cancer Therapy Market, by Country

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Lung Cancer Therapy Market - Key Industry Dynamics

4.1 Market Drivers:
- 4.1.1 Increase in Cases of Lung Cancer
- 4.1.2 Government Initiatives for Screening and Treatment of Lung Cancer
4.2 Market Restraints
- 4.2.1 High Cost of Lung Cancer Therapy
4.3 Market Opportunities
- 4.3.1 Rising Number of Lung Cancer Therapy in Clinical Trials
4.4 Future Trends
- 4.4.1 Growing Demand for Targeted Therapy
4.5 Impact Analysis:

5. Lung Cancer Therapy Market - North America Market Analysis

5.1 North America Lung Cancer Therapy Market Revenue (US$ Mn), 2020 - 2030

6. North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

6.1 Overview
6.2 North America Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
6.3 Non-Invasive Therapy
- 6.3.1 Overview
- 6.3.2 Non-Invasive Therapy: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Minimally Invasive
- 6.4.1 Overview
- 6.4.2 Minimally Invasive: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- 6.4.3 North America Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)

7. North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by Indication

7.1 Overview
7.2 North America Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
7.3 Non-Small Cell Lung Cancer
- 7.3.1 Overview
- 7.3.2 Non-Small Cell Lung Cancer: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Small Cell Lung Cancer
- 7.4.1 Overview
- 7.4.2 Small Cell Lung Cancer: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by End User

8.1 Overview
8.2 North America Lung Cancer Therapy Market Revenue Share, by End User, 2022 & 2030 (%)
8.3 Hospitals
- 8.3.1 Overview
- 8.3.2 Hospitals: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Oncology Clinics
- 8.4.1 Overview
- 8.4.2 Oncology Clinics: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Research Centers
- 8.5.1 Overview
- 8.5.2 Research Centers: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Lung Cancer Therapy Market - Country Analysis

9.1.1 North America North America Lung Cancer Therapy Market, by Country
- 9.1.1.1 US
  - 9.1.1.1.1 Overview
  - 9.1.1.1.2 US: North America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.1.3 US: North America Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.1.3.1 US: North America Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.1.4 US: North America Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.1.5 US: North America Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.2 Canada
  - 9.1.1.2.1 Overview
  - 9.1.1.2.2 Canada: North America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.2.3 Canada: North America Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.2.3.1 Canada: North America Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.2.4 Canada: North America Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.2.5 Canada: North America Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.3 Mexico
  - 9.1.1.3.1 Overview
  - 9.1.1.3.2 Mexico: North America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.3.3 Mexico: North America Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.3.3.1 Mexico: North America Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.3.4 Mexico: North America Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.3.5 Mexico: North America Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)

10. Lung Cancer Therapy Market - Industry Landscape

10.1 Overview
10.2 Growth Strategies in North America Lung Cancer Therapy Market
10.3 Inorganic Growth Strategies
- 10.3.1 Overview
10.4 Organic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Medtronic Plc
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 RF Medical Co Ltd
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Johnson & Johnson
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Merck KGaA
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Sun Pharmaceutical Industries Ltd
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Bioventus Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Olympus Corp
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Meiji Seika Pharma Co Ltd
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Advanz Pharma Corp
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms

简介目录图表

List Of Tables

Table 1. North America Lung Cancer Therapy Market Segmentation
Table 2. North America Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 3. US North America Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 4. US: North America Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 5. US: North America Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 6. US: North America Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 7. Canada: North America Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 8. Canada: North America Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 9. Canada: North America Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 10. Canada: North America Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 11. Mexico: North America Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 12. Mexico: North America Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 13. Mexico: North America Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 14. Mexico: North America Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 15. Recent Inorganic Growth Strategies in the North America Lung Cancer Therapy Market
Table 16. Recent Organic Growth Strategies in North America Lung Cancer Therapy Market
Table 17. Glossary of Terms, North America Lung Cancer Therapy Market

List Of Figures

Figure 1. North America Lung Cancer Therapy Market Segmentation, By Country
Figure 2. North America Lung Cancer Therapy Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America Lung Cancer Therapy Market Revenue (US$ Mn), 2020 - 2030
Figure 5. North America Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
Figure 6. Non-Invasive Therapy: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Minimally Invasive: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. North America Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
Figure 9. Non-Small Cell Lung Cancer: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Small Cell Lung Cancer: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. North America Lung Cancer Therapy Market Revenue Share, End User, 2022 & 2030 (%)
Figure 12. Hospitals: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Oncology Clinics: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Research Centers: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: North America Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. North America: North America Lung Cancer Therapy Market, by Key Country - Revenue (2022) (US$ Million)
Figure 17. North America North America Lung Cancer Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 18. US: North America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 19. Canada: North America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 20. Mexico: North America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Growth Strategies in North America Lung Cancer Therapy Market